Suppr超能文献

肺炎链球菌编码DNA拓扑异构酶IV的parC和parE基因的克隆与特性分析:在氟喹诺酮耐药性中的作用

Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

作者信息

Pan X S, Fisher L M

机构信息

Molecular Genetics Group, Department of Cellular and Molecular Sciences, St. George's Hospital Medical School, University of London, United Kingdom.

出版信息

J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996.

Abstract

DNA topoisomerase IV mediates chromosome segregation and is a potential target for antibacterial agents including new antipneumococcal fluoroquinolones. We have used hybridization to a Staphylococcus aureus gyrB probe in concert with chromosome walking to isolate the Streptococcus pneumoniae parE-parC locus, lying downstream of a putative new insertion sequence and encoding 647-residue ParE and 823-residue ParC subunits of DNA topoisomerase IV. These proteins exhibited greatest homology respectively to the GrlB (ParE) and GrlA (ParC) subunits of S. aureus DNA topoisomerase IV. When combined, whole-cell extracts of Escherichia coli strains expressing S. pneumoniae ParC or ParE proteins reconstituted a salt-insensitive ATP-dependent decatenase activity characteristic of DNA topoisomerase IV. A second gyrB homolog isolated from S. pneumoniae encoded a 648-residue protein which we identified as GyrB through its close homology both to counterparts in S. aureus and Bacillus subtilis and to the product of the S. pneumoniae nov-1 gene that confers novobiocin resistance. gyrB was not closely linked to gyrA. To examine the role of DNA topoisomerase IV in fluoroquinolone action and resistance in S. pneumoniae, we isolated mutant strains stepwise selected for resistance to increasing concentrations of ciprofloxacin. We analysed four low-level resistant mutants and showed that Ser-79 of ParC, equivalent to resistance hotspots Ser-80 of GrlA and Ser-84 of GyrA in S. aureus, was in each case substituted with Tyr. These results suggest that DNA topoisomerase IV is an important target for fluoroquinolones in S. pneumoniae and establish this organism as a useful gram-positive system for resistance studies.

摘要

DNA拓扑异构酶IV介导染色体分离,是包括新型抗肺炎球菌氟喹诺酮类药物在内的抗菌剂的潜在靶点。我们利用与金黄色葡萄球菌gyrB探针的杂交技术,并结合染色体步移法,分离出肺炎链球菌parE-parC基因座,该基因座位于一个假定的新插入序列下游,编码DNA拓扑异构酶IV的647个氨基酸残基的ParE亚基和823个氨基酸残基的ParC亚基。这些蛋白质分别与金黄色葡萄球菌DNA拓扑异构酶IV的GrlB(ParE)和GrlA(ParC)亚基具有最高的同源性。当将表达肺炎链球菌ParC或ParE蛋白的大肠杆菌菌株的全细胞提取物混合时,可重建DNA拓扑异构酶IV特有的对盐不敏感的ATP依赖性解连环酶活性。从肺炎链球菌中分离出的第二个gyrB同源物编码一个648个氨基酸残基的蛋白质,通过其与金黄色葡萄球菌和枯草芽孢杆菌中的对应物以及赋予新生霉素抗性的肺炎链球菌nov-1基因产物的密切同源性,我们将其鉴定为GyrB。gyrB与gyrA没有紧密连锁。为了研究DNA拓扑异构酶IV在肺炎链球菌氟喹诺酮作用和耐药性中的作用,我们逐步分离出对环丙沙星浓度增加具有抗性的突变菌株。我们分析了四个低水平抗性突变体,结果表明ParC的79位丝氨酸,相当于金黄色葡萄球菌中GrlA的80位丝氨酸和GyrA的84位丝氨酸耐药热点,在每种情况下都被酪氨酸取代。这些结果表明,DNA拓扑异构酶IV是肺炎链球菌中氟喹诺酮类药物的重要靶点,并将该生物体确立为耐药性研究的有用革兰氏阳性系统。

相似文献

引用本文的文献

10
In front of and behind the replication fork: bacterial type IIA topoisomerases.复制叉的前后:细菌 IIA 拓扑异构酶。
Cell Mol Life Sci. 2010 Jun;67(12):2001-24. doi: 10.1007/s00018-010-0299-5. Epub 2010 Feb 18.

本文引用的文献

7
New quinolones and gram-positive bacteria.新型喹诺酮类药物与革兰氏阳性菌
Antimicrob Agents Chemother. 1994 Feb;38(2):163-9. doi: 10.1128/AAC.38.2.163.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验